Boardroom Alpha
8-K/A primary document
BDX · Amended Current Report (Form 8-K/A) · Filed May 7, 2026

Becton Dickinson & Co8-K/A exhibit

ex991bdcfopressrelease.htm
Document

Exhibit 99.1

NEWS RELEASE image_0a.jpg
BD Appoints Vitor Roque Chief Financial Officer
FRANKLIN LAKES, N.J. (May 7, 2026) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vitor Roque has been named executive vice president and chief financial officer (CFO), effective May 7. Roque has served as interim CFO since December 2025.
With more than 25 years at BD, Roque has held senior finance and operations roles across the company, most recently as senior vice president, Finance and Corporate Financial Planning and Analysis. During his tenure as interim CFO, he led BD’s global finance function and helped advance key priorities under the New BD strategy, including completing the separation of BD’s Biosciences & Diagnostic Solutions business ahead of schedule.
“Following a comprehensive search process, it was clear that Vitor is the right leader to serve as BD’s next CFO, reflecting both his capabilities and the strength of our leadership pipeline,” said Tom Polen, chairman and CEO of BD. “Vitor brings an unmatched understanding of our business, a proven ability to translate strategy into performance and the discipline to drive consistent execution at scale. He has been an important leader in advancing our transformation and strengthening financial performance, and I'm confident he will help us deliver the next phase of growth and create long-term value for our shareholders and customers.”
Roque brings deep institutional knowledge and a track record of finance leadership roles supporting operations, manufacturing, regions and business units. His comprehensive understanding of BD’s portfolio, global footprint and operating model has been built through direct, handson leadership across the enterprise. Having lived and worked in multiple countries, Roque brings a strong appreciation for the cultural and regional dynamics essential to BD’s success as a global organization. This combination of global perspective and execution experience positions him to continue elevating financial discipline, increasing organizational speed and supporting consistent, highquality execution as BD advances its strategy.
“This is an important moment for BD, and I'm honored to step into this role as we accelerate on our progress,” said Roque. “After more than two decades with the company, I see tremendous opportunity ahead – with a clear, welldefined strategy to unlock significant growth and increase our impact on global healthcare. With a strong operating foundation, disciplined financial management, and focused execution, BD is well positioned to drive consistent performance, deliver durable growth and increase shareholder value creation as we continue to deliver on our purpose of advancing the world of health.”
# # #



About BD
BD is one of the world’s largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts:

Media
Investors
Megan Dubrowski
Senior Director, Executive Communications
Megan.Dubrowski@bd.com
Shawn Bevec
SVP, Investor Relations
Investor_Relations@bd.com

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer